Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06616974 | A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | PHASE2 | RECRUITING | 180 | — | — | Sep 1, 2024 | Nov 1, 2026 | Jan 29, 2026 | - | — |
| Name | Type | Description |
|---|---|---|
| TX000045- Dose A | DRUG | The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks. |
| TX000045- Dose B | DRUG | The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks. |
| Placebo | DRUG | The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks. |